ANNX
Next earnings: Aug 13, 2026 · Before open
Signal
Bearish Setup2
Price
1
Move-2.98%Negative session
Volume
1
Volume0.7× avgNormal activity
Technical
1
RSIRSI 41Momentum negative
PRICE
Prev Close
5.37
Open
5.25
Day Range5.06 – 5.37
5.06
5.37
52W Range1.85 – 7.18
1.85
7.18
63% of range
VOLUME & SIZE
Avg Volume
2.5M
FUNDAMENTALS
P/E Ratio
-4.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.12
Market-like
Performance
1D
-2.98%
5D
-7.30%
1M
-17.95%
3M
+6.54%
6M
+92.25%
YTD
+3.78%
1Y
+187.85%
Best: 1Y (+187.85%)Worst: 1M (-17.95%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 6.4 · FCF negative
Neutral
Key MetricsTTM
Market Cap$623.09M
Revenue TTM$0.00
Net Income TTM-$196.48M
Free Cash Flow-$183.16M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-101.2%
Return on Assets-74.7%
Debt / Equity0.12
Current Ratio6.35
EPS TTM$-1.01

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
49/100
Liquidity
6.35Strong
Leverage
0.12Strong
Coverage
0.0xConcern
ROE
-101.2%Concern
ROIC
-89.2%Concern
Cash
$162MStrong
ANALYST COVERAGE10 analysts
BUY
+120.7%upside to target
L $7.00
Med $11.50consensus
H $16.00
Buy
10100%
10 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
RSI RangeRSI 41 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 6.35 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 31, 2026
In 106 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

PullbackGolden Cross · 50D leads 200D by 30.1%

-8.8% vs SMA 50 · +18.6% vs SMA 200

Momentum

RSI40.6
Momentum fading
MACD-0.11
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$7.18+37.8%
EMA 50
$5.68+9.1%
Current
$5.21
EMA 200
$4.43-15.0%
52W Low
$1.85-64.5%
52-Week RangeMid-range
$1.8563th %ile$7.18
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:1
Dist days:1
Edge:Even
Volume Context
Avg Vol (50D)2.4M
Recent Vol (5D)
1.8M-24%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 7 analysts
Analyst revisions:EPS↓ Revised DownRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$10.8M
$2.8M$25.3M
-$1.38
±3%
High6
FY2026(current)
$2.4M
$601495$5.5M
-78.2%-$0.95
±11%
High6
FY2027
$45.0M
$9.1M$106.8M
+1802.8%-$0.80
±42%
High7
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryANNX
Last 8Q
-0.6%avg beat
Beat 4 of 8 quartersMissed 3 Estimates falling
Q3'24
+4%
Q4'24
-18%
Q1'25
-23%
Q2'25
+6%
Q3'25
-9%
Q4'25
+12%
Q1'26
+23%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
BarclaysOverweight
May 13
UPGRADE
Leerink PartnersMarket Perform
May 13
DOWNGRADE
Bank of America Sec…Buy
Dec 21
UPGRADE
Insider Activity
SEC Filings →
3 Buys/3 SellsNeutral
NET BUYERS$46K bought · $0 sold · 30d window
Carson William H.Dir
$46K
May 11
BUY
Carson William H.Dir
$50K
Apr 10
BUY
Carson William H.Dir
$45K
Mar 10
BUY
Dananberg JamieCHIEF MEDICAL …
$32K
Mar 2
SELL
Overdorf MichaelEVP & CHIEF BU…
$24K
Mar 2
SELL
Yednock TedEVP & CHIEF IN…
$30K
Mar 2
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
BlackRock, Inc.
10.9M
2
Nuveen, LLC
4.2M
3
Siren, L.L.C.
4.0M
4
Y-Intercept (Hong Kong) Ltd
1.3M
5
UBS Group AG
1.2M
6
NORTHERN TRUST CORP
1.1M
7
DIMENSIONAL FUND ADVISORS LP
924K
8
KENNEDY CAPITAL MANAGEMENT LLC
912K
News & Activity

ANNX News

About

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a rigorous, biomarker-driven development strategy designed to improve the probability of technical success over shorter development timelines.

Industry
Pharmaceutical Preparation Manufacturing
Jamie DananbergExecutive Vice President & Chief Medical Officer
Lloyd ClarkSenior Vice President of Ophthalmology Strategy & Innovation
Ted YednockExecutive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
ANNX
$5.21-2.98%$623M1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.30%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-2.97%50.3+398824.8%-4085.6%1500